New ODYSSEY results show that dolutegravir cut treatment failure in children with HIV (19% vs 34% at 240 weeks) and showed no new safety problems.
A hopeful step for stronger, simpler care for kids worldwide!
More 👉 https://academic.oup.com/ofid/article/13/5/ofag266/8669861
